
Poster Title: Evaluating the Relationship Between Esketamine Monotherapy Efficacy and Dissociation in Patients With Treatment-Resistant Depression

Is there a relationship between esketamine efficacy and dissociation?

- A new generation of antidepressants, including esketamine, have unique dissociative side effects that can lead to functional unblinding, which can confound the assessment of efficacy.
- Chen et al. 2022 reported no significant relationship between dissociation and esketamine efficacy as an adjunctive therapy in participants with TRD assessed by the CADSS.
- It is of interest to explore the association between dissociation and esketamine monotherapy.
- Methodological focus: Evaluate the relationship between dissociation and esketamine monotherapy efficacy in participants with TRD assessed by TEAE reports of dissociation.

Figure 1. No significant difference between responders without and with dissociation at different timepoints



Responder = ≥50% improvement in MADRS total score CADSS total score >4 = presence dissociative symptoms

Abbreviations: Treatment-Resistant Depression (TRD), Clinician-Administered Dissociation States Scale (CADSS), Treatment-Emergent Adverse Event (TEAE)

Poster Title: Evaluating the Relationship Between Esketamine Monotherapy Efficacy and Dissociation in Patients With Treatment-Resistant Depression

Dissociation does not appear to impact esketamine monotherapy efficacy

What we did

Conducted a post-hoc analysis to evaluate the relationship between esketamine monotherapy efficacy and dissociation in adults with TRD assessed by TEAE reports of dissociation.



No significant difference between response rates in participants with and without dissociation for both esketamine treatment groups.

(p=1.000 and p=0.796)



Esketamine efficacy is not dependent on dissociation.

Figure 2. Response rates among participants with and without dissociation by treatment groups

| | Dissociation | No Dissociation |
|---------------------|--------------|-----------------|
| Placebo | | |
| N | 7 | 190 |
| Responder | 3 (42.9%) | 27 (14.2%) |
| Fisher's Exact test | | P=0.073 |
| Esketamine 56 mg | | |
| N | 19 | 66 |
| Responder | 6 (31.6%) | 20 (30.3%) |
| Fisher's Exact test | | P=1.000 |
| Esketamine 84 mg | | |
| N | 23 | 72 |
| Responder | 7 (30.4%) | 20 (27.8%) |
| Fisher's Exact test | | P=0.796 |